



S.F. No. 2370 – Cannabis Policy Omnibus Bill (as amended by the A1 Delete Everything amendment)

Author: Senator D. Scott Dibble

Prepared by: Olivia Syverson, Senate Counsel (olivia.syverson@mnsenate.gov)

Date: March 31, 2025

Section 1 (SF 1730, section 1, amends section 10.65, subdivision 2) adds the Office of Cannabis Management to the definition of “agency” in section 10.65, subdivision 2.

Section 10.65 outlines the government-to-government relationship with tribal governments. As an agency under section 10.65, the Office of Cannabis Management must comply with the consultation duties of this section.

Section 2 (SF 1729, as amended by the a1, section 1, amends section 151.72, subdivision 3) allows products containing nonintoxicating cannabinoids to be sold for human or animal consumption only if it is intended for application externally to a part of the body of a human or animal. It may not be manufactured, marketed, distributed, or intended to be consumed through injection or application to nonintact skin or a mucous membrane, except for products applied sublingually.

Section 3 (SF 2370, section 1, amends 151.72, subdivision 5a) amends the temporary regulations of edible cannabinoid products to authorize products intended to be consumed as a beverage to contain up to ten milligrams of any tetrahydrocannabinol in a single service container.

Section 4 (SF 2372, as amended by the a1, section 1, amends section 152.22, subdivision 4) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 5 (SF 2372, as amended by the a1, section 2, amends section 152.22, subdivision 7) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 6 (SF 2372, as amended by the a1, section 3, amends section 152.22, subdivision 10) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 7 (SF 2372, as amended by the a1, section 4, amends section 152.22, subdivision 13) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 8 (SF 2372, as amended by the a1, section 5, amends section 152.24) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 9 (SF 2372, as amended by the a1, section 6, amends section 152.25) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 10 (SF 2372, as amended by the a1, section 7, amends section 152.26) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 11 (SF 2372, as amended by the a1, section 8, amends section 152.261) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 12 (SF 2372, as amended by the a1, section 9, amends section 152.27, subdivision 2) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 13 (SF 2372, as amended by the a1, section 10, amends section 152.27, subdivision 7) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 14 (SF 2372, as amended by the a1, section 11, amends section 152.28, subdivision 1) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 15 (SF 2372, as amended by the a1, section 12, amends section 152.28, subdivision 3) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 16 (SF 2372, as amended by the a1, section 13, amends section 152.29, subdivision 1) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 17 (SF 2372, as amended by the a1, section 14, amends section 152.29, subdivision 2) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 18 (SF 2372, as amended by the a1, section 15, amends section 152.29, subdivision 3a) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 19 (SF 2372, as amended by the a1, section 16, amends section 152.29, subdivision 4) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 20 (SF 2372, as amended by the a1, section 17, amends section 152.31) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 21 (SF 2372, as amended by the a1, section 18, amends section 152.32, subdivision 2) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 22 (SF 2372, as amended by the a1, section 19, amends section 152.33, subdivision 1a) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 23 (SF 2372, as amended by the a1, section 20, amends section 152.33, subd. 4) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 24 (SF 2372, as amended by the a1, section 21, amends section 152.35) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 25 (SF 2372, as amended by the a1, section 22, amends section 152.37) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 26 (SF 2372, as amended by the a1, section 23, amends section 342.01, subdivision 9) makes technical and conforming changes to reflect the transfer of the medical cannabis program from the Department of Health to the Office of Cannabis Management.

Section 27 (SF 2372, as amended by the a1, section 24, amends section 342.01, subdivision 47) amends the definition of “labor peace agreement” to include the requirement that a lower-potency hemp edible manufacturer have an agreement with a labor organization.

Section 28 (SF 2370, section 2, amends section 342.01, subdivision 50) amends the definition of lower-potency hemp edible to include products intended to be consumed as a beverage that contain up to ten milligrams of any tetrahydrocannabinol in a single service container.

Section 29 (SF 2372, as amended by the a1, section 25, amends section 342.01, subdivision 54) amends the definition of “medical cannabis flower” to remove language referring to medical cannabis flower being provided to a visiting patient.

Section 30 (SF 2372, as amended by the a1, section 26, amends section 342.01, subdivision 54a) defines “medical cannabis paraphernalia.”

Section 31 (SF 2371-1, section 1, amends section 342.01, subdivision 69c) defines “tribal medical cannabis board.”

Section 32 (SF 2371-1, section 2, amends section 342.01, subdivision 69d) defines “tribal medical cannabis program.”

Section 33 (SF 2371-1, section 3, amends section 342.01, subdivision 69e) defines “tribal medical cannabis program patient.

Section 34 (SF 2372, as amended by the a1, section 27, amends section 342.02, subdivision 3) strikes an obsolete effective date.

Section 35 (SF 2371-1, section 4, amends section 342.09, subdivision 2) allows a registered designated caregiver to cultivate up to eight cannabis plants for no more than one patient household. In addition, a registered designated caregiver may cultivate up to eight cannabis plants for the caregiver’s personal adult use of cannabis.

Section 36 (SF 2372, as amended by the a1, section 28, amends section 342.12) makes technical and conforming changes to align with statutory changes made in 2024.

Section 37 (SF 1731, section 1, amends section 342.14, subdivision 1) requires applicants to provide proof that the applicant is a social equity applicant and provide an attestation that the applicant’s business policies governing business operations comply with this chapter.

Removes the requirement that an application on behalf of a corporation or association shall be signed by at least two officers or managing agents of that entity.

Section 38 (SF 2372, as amended by the a1, section 29 amends section 342.14, subdivision 3) makes a conforming change related to the timing of fees related to changes made in 2024.

Section 39 (SF 2372, as amended by the a1, section 30, amends section 342.14, subdivision 6) makes a technical change to correct the description of preliminary license approval.

Section 40 (SF 2372, as amended by the a1, section 31, amends section 342.151, subdivision 2) makes technical changes to reflect that cannabis businesses must perform background checks on potential employees, but the requirement does not apply to hemp businesses.

Section 41 (SF 2372, as amended by the a1, section 32, amends section 342.151, subdivision 3) makes technical changes to reflect that cannabis businesses may be disqualified after a background check, but the disqualification does not apply to employees of hemp businesses.

Section 42 (SF 2372, as amended by the a1, section 33, amends section 342.22, subdivision 3) makes a technical change to correct the description of preliminary license approval.

Section 43 (SF 2372, as amended by the a1, section 34, amends section 342.28, subdivision 1) authorizes a cannabis microbusiness to purchase products that contain cannabinoids from other cannabis and hemp businesses.

Section 44 (SF 2372, as amended by the a1, section 35, amends section 342.28, subdivision 8) makes a technical correction.

Section 45 (SF 2372, as amended by the a1, section 36, amends section 342.29, subdivision 1) authorizes a cannabis mezzobusiness to purchase products that contain cannabinoids from other cannabis and hemp businesses. Makes a technical correction.

Section 46 (SF 2372, as amended by the a1, section 37, amends section 342.29, subdivision 7) makes technical corrections.

Section 47 (SF 2372, as amended by the a1, section 38, amends section 342.30, subdivision 1) authorizes cannabis cultivators to sell immature plants and seedlings to other cannabis businesses. Makes technical changes.

Section 48 (SF 2372, as amended by the a1, section 39, amends section 342.33, subdivision 1) makes a technical correction authorizing cannabis wholesalers to purchase certain products from lower-potency hemp manufacturers.

Section 49 (SF 2372, as amended by the a1, section 40, amends section 342.44, subdivision 1) removes the requirement that the form and procedure for hemp licenses be established by rule.

Section 50 (SF 1729, as amended by the a1, section 2, amends section 342.45, subdivision 6) requires lower-potency hemp edible manufacturers to comply with state and local building, fire, and zoning codes, requirements, and regulations.

Lower-potency hemp edible manufacturers must ensure that licensed premises are maintained in a clean and sanitary condition and are free from infestation by insects, rodents, or other pests.

Section 51 (SF 2370, section 3, and SF 2372, section 41, amends section 342.46, subdivision 6) amends the permanent regulations of lower-potency hemp edibles to

authorize products intended to be consumed as a beverage to contain up to ten milligrams of delta-9 tetrahydrocannabinol in a single service container.

Makes technical changes to the requirements related to determining the number of servings in a package of lower-potency hemp edibles.

Section 52 (SF 2371-1, section 5, amends section 342.51, subdivision 2) modifies the requirements that must be satisfied before distributing medical cannabis flower or medical cannabinoid products. In addition to the current requirements, a cannabis business must confirm that the patient had a consultation with an employee with a valid medical cannabis consultant certificate issued by the office or an employee who is a licensed pharmacist under chapter 151.

Section 53 (SF 2371-1, section 6, amends section 342.51, subdivision 2a) provides for the distribution of medical cannabis flower or medical cannabinoid products to a Tribal medical cannabis program patient by a cannabis business with a medical cannabis retail endorsement.

A Tribal medical cannabis program patient must provide to an employee of the cannabis business a valid medical cannabis registration verification card and a valid photo ID issued by the Tribal medical cannabis program.

An employee of a cannabis business must ensure that a patient-specific label has been applied to all medical cannabis flower and medical cannabinoid products and provide any other required information.

A cannabis business with a medical cannabis retail endorsement is required to report to the office certain information on a weekly basis, for each transaction that involves a Tribal medical cannabis program patient.

A cannabis business with a medical cannabis retail endorsement may distribute medical cannabis flower and medical cannabinoid products to a Tribal medical cannabis program patient in a motor vehicle if several requirements are met.

Section 54 (SF 2372, as amended by the a1, section 42, amends section 342.52, subdivision 7a) allows patients in the registry program to receive medical cannabis flower and medical cannabinoid products, and allows the office to approve additional delivery methods for medical cannabinoid products.

Section 55 (SF 2371-1, section 7, amends section 342.52, subdivision 9) requires a patient who assigns the patient's right to cultivate cannabis plants to a designated caregiver to notify the office of that assignment. A patient who assigns their right's is prohibited from cultivating cannabis plants for their personal use.

Section 56 (SF 2371-1, section 8 and SF 2372, as amended by the a1, amend section 342.57) modifies several provisions related to the protections for registry program participants.

Provides a presumption that a Tribal medical cannabis program patient's is engaged in the authorized use or possession of medical cannabis flower or medical cannabinoid products.

Provides a Tribal medical cannabis program patient's use or possession of medical cannabis flower, medical cannabinoid products, or paraphernalia is not a violation of chapter 152 if distributed under section 342.51, subd. 5.

Removes language providing use or possession of medical cannabis flower, medical cannabinoid products, or medical cannabis paraphernalia by visiting patients to whom these items are distributed under section 342.51, subdivision 5, does not violate chapter 152 or chapter 342.

Provides members of a Tribal medical cannabis board, board staff, and agents and contractors are not subject to civil penalties or disciplinary action by a business, occupational, or professional licensing board for participating in a Tribal medical cannabis program.

Prohibits information obtained from a Tribal medical cannabis program patient from being admitted as evidence in a criminal proceeding unless the information is independently obtained and the proceeding involves a violation of the medical cannabis program statutes.

Provides possession of a verification issued by a Tribal medical cannabis program or an application for enrollment in a Tribal medical cannabis program, by a person entitled to possess the verification or application, does not constitute probable cause or reasonable suspicion, must not be used to support a search, and must not subject the person or property to inspection by a government agency.

Prohibits an employer from discriminating against a person in hiring, termination, or a term or condition of employment based on the person's status as a Tribal medical cannabis program patient, and allows Tribal medical cannabis program patients to present verification from their Tribal medical cannabis program to explain a positive drug test result to an employer.

Prohibits a person from being denied custody, visitation, or parenting time based on the person's status as a Tribal medical cannabis program patient.

Prohibits the commissioner of corrections from prohibiting an individual from participating in a Tribal medical cannabis program, or revoking an individual's parole, supervised release, or conditional release for participating in a Tribal medical cannabis program.

Provides a patient enrolled in the registry program must not be subject to a penalty or disciplinary action by an occupational or professional licensing board solely because the patient is enrolled in the registry program or has a positive test for cannabis components or metabolites.

Prohibits a school from penalizing or refusing to enroll a patient as a pupil solely because cannabis is a controlled substance under federal law, and prohibits a landlord from

penalizing or refusing to lease property to a patient solely because cannabis is a controlled substance under federal law.

Requires employers, schools, and landlords to provide at least 14 days' written notice before taking certain actions against a patient, and specifies what the notice must include. Prohibits schools, landlords, health care facilities, and employers from retaliating against patients for asserting their rights or seeking remedies.

Allows a patient to bring an action for injunctive relief to prevent or end a violation of subdivisions 3 to 6a, and increases the minimum civil penalty amount from \$100 to \$1,000.

Section 57 (SF 2372, as amended by the a1, section 44, amends section 342.59, subdivision 2) corrects a cross-reference.

Section 58 (SF 2372, as amended by the a1, section 45, amends section 342.61, subdivision 4) makes a technical change.

Section 59 (SF 2372, as amended by the a1, section 46, amends section 342.63, subdivision 2) removes the option of listing the volume of cannabis flower in a container. The label must indicate the net weight.

Section 60 (SF 2372, as amended by the a1, section 47, amends section 342.63, subdivision 3) includes hemp concentrate in the list of products that must have certain information on a label. Removes the option of listing the volume of products in a container. The label must indicate the net weight.

Section 61 (SF 1729, as amended by the a1, section 3, amends section 342.63, subdivision 5) strikes language that allows certain information to be provided through the use of a scannable barcode.

Section 62 (SF 2372, as amended by the a1, section 48, amends section 342.63, subdivision 6) authorizes cannabis businesses making sales directly to customers to include certain information on a product's label. Currently, some information must be on the label and other information must either be posted on the business premises or provided as part of a separate document.

Section 63 (SF 1729, as amended by the a1, section 4, amends section 342.66, subdivision 6) states that hemp-derived topical products must not be manufactured, marketed, distributed, or intended to be consumed through injection or application to nonintact skin or a mucous membrane, except for products applied sublingually.

Section 64 (SF 2372, as amended by the a1, section 49, Repealer) repeals the following statutes:

- (1) section 152.22, subd. 2 (definition of commissioner in the medical cannabis statutes in chapter 152);
- (2) section 342.01, subd. 71 (definition of visiting patient in chapter 342); and
- (3) 342.151, subd. 1 (definition of license holder).



Senate Counsel, Research, and Fiscal Analysis provides nonpartisan legislative, legal, fiscal, and analytical services to the Minnesota Senate. This document can be made available in different formats upon request.

www.senate.mn/scrfa/home | 651-296-4791
95 University Ave. W., STE 3300, Saint Paul, MN, 55155